Literature DB >> 9368312

Therapy of radiation injury.

T J MacVittie1.   

Abstract

It is apparent from preclinical and clinical research to date that continued evaluation of new and alternative treatment strategies is required to eliminate the obligate periods of neutropenia and thrombocytopenia after acute high-dose irradiation. Future treatment strategies may involve new combinations of cytokines to affect hematopoietic stem cell proliferation and "engineered" cellular grafts to provide short-term in vivo expansion of neutrophils and platelets in an effort to bridge the cytopenic gap until endogenous or transplanted stem cells regenerate the hematopoietic and immune systems. Cytokine-mobilized peripheral blood and cord blood will provide alternative sources of allogeneic stem and progenitor cells in support of primary engraftment, delayed engraftment or secondary failure of the initial graft, as well as starting populations for various ex vivo expansion protocols. Further insights into the relative quality of stem cell populations and the factors that regulate their survival and self renewal, and the identification and roles of adhesion molecules in stem cell mobilization, engraftment, and interaction with the adult marrow microenvironment will provide the basis for future treatment strategies for the radiation-induced hematopoietic syndrome. As our ability to treat the hematopoietic syndrome improves, damage to other organ systems such as the skin, lung, and/or gastrointestinal tissue will emerge as dose-limiting. At the same time, the characterization of receptors for inflammatory cytokines, cytokine receptor antagonists, and anti-endotoxin antibodies has allowed significant insights into the mechanisms and pathogenesis of sepsis. However, translation of this knowledge into a treatment modality for septic patients is precluded by the lack of any clear-cut beneficial effect from the many clinical trials. The research and clinical results presented in this volume and recent conferences reflect the body of knowledge that will lead to further developments in assessment, prophylaxis, and treatment of radiation injuries in the areas of infectious disease and the hematopoietic, gastrointestinal, and cutaneous syndromes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368312     DOI: 10.1002/stem.5530150735

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  4 in total

1.  The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury.

Authors:  K X Hu; Q Y Sun; M Guo; H S Ai
Journal:  Br J Radiol       Date:  2010-01       Impact factor: 3.039

Review 2.  Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.

Authors:  Elvira C van Dalen; Arno Mank; Edith Leclercq; Renée L Mulder; Michelle Davies; Marie José Kersten; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2016-04-24

3.  Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation.

Authors:  Lurong Zhang; Weimin Sun; Jianjun Wang; Mei Zhang; Shanmin Yang; Yeping Tian; Sadasivan Vidyasagar; Louis A Peña; Kunzhong Zhang; Yongbing Cao; Liangjie Yin; Wei Wang; Lei Zhang; Katherine L Schaefer; Lawrence J Saubermann; Steven G Swarts; Bruce M Fenton; Peter C Keng; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-01       Impact factor: 7.038

4.  Multiplacenta derived stem cell/cytokine treatment increases survival time in a mouse model with radiation-induced bone marrow damage.

Authors:  Jun Li; Yunfang Wei; Lei Yan; Rui Wang; Ying Zhang; Yingzhen Su; Zhaoyu Yang; Min Hu; Rui Qi; Hongbo Tan; Qiong Wu; Xudong Yin; Xinghua Pan
Journal:  Cytotechnology       Date:  2016-06-18       Impact factor: 2.058

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.